Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study
Background Type 2 diabetes mellitus (T2DM) is a condition involving several molecular mechanisms related to the intestinal microbiota for its development. Intestinal fatty acid‐binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. A prebiotic is a non‐digestible food ingredient...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical laboratory analysis 2020-11, Vol.34 (11), p.e23490-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | e23490 |
| container_title | Journal of clinical laboratory analysis |
| container_volume | 34 |
| creator | Hou, Yi‐Cheng Lai, Chien‐Wen Cheng, Ching‐Feng Lin, Yi‐Ying Hsieh, Tsung‐Han Hui Wu, Jing Tzeng, I‐Shiang Kuo, Chan‐Yen |
| description | Background
Type 2 diabetes mellitus (T2DM) is a condition involving several molecular mechanisms related to the intestinal microbiota for its development. Intestinal fatty acid‐binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. A prebiotic is a non‐digestible food ingredient that improves host health by selectively stimulating the growth and/or activities of bacteria in the colon. We aimed to clarify the currently described effects of prebiotics in the prevention and management of T2DM.
Methods
In this case‐control study, we chose 68 participants with T2DM and 52 healthy participants. Both groups were further divided based on consumption of prebiotics. Forty participants with T2DM consumed prebiotics, and 28 did not; 30 healthy volunteers consumed prebiotics, and 22 did not. We used the analysis of variance to compare the inflammation levels between the case and control groups. Multiple linear regression was performed for the significantly correlated groups to estimate the influence of prebiotics on inflammation level.
Results
Age was a significant factor for difference in I‐FABP levels (standardized coefficient: 0.06; P = .047). The analysis of eating habits showed that vegetarian diets produced lower I‐FABP levels than non‐vegetarian diets (standardized coefficient: −2.55; P = .022). Results showed that patients with T2DM who consumed prebiotics expressed lower I‐FABP levels, reflecting an improvement in inflammation level, than the healthy volunteers who did not consume prebiotics (standardized coefficient: −3.20; P = .019).
Conclusions
For patients with T2DM, prebiotics supplemented produced no significant impact on serum I‐FABP levels.
To evaluate effects of prebiotics in the prevention and management T2DM, totally 120 patients were recruited for the initial screening with I‐FABP. The participants in this study had no history of gastrointestinal disease and had not been treated with antibiotics or laxatives within 3 months before the experiment; all T2DM patients received dietary advice to control and treat diabetes. Blood or urine samples were collected at baseline and at 1, 3, and 6 months, followed by proper statistical analysis. |
| doi_str_mv | 10.1002/jcla.23490 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7676185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2606941864</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4350-eba121daee400e6aaf2d8166c521aed1f16b20891f92da8d95a6122622879bd13</originalsourceid><addsrcrecordid>eNp9ksuKFDEUQIMoTju68QMk4EaEGpNUVSrlQmia8UWDG12HVHJrJk0qaZPUDL1z7cpv9EtM2eOgLgYCWeTccx-5CD2l5IwSwl7ttFNnrG56cg-tKOlFxQRr76MVEaKrBKH1CXqU0o4QInrKH6KTmvGet5yt0PfzcQSdEw4j3kcYbMhWYx18mqd9tsHjchLEecLWZ0jZeuXwqHI-YKWt-fntx2C9sf6ihIcM1mMHV-BSwfFeZQu-yK9tvsTGqgGK4jVeY60SlNCSJ8fgcMqzOTxGD0blEjy5uU_Rl7fnnzfvq-2ndx82622lm7olFQyKMmoUQEMIcKVGZgTlXLeMKjB0pHxgS6Njz4wSpm8Vp4xxxkTXD4bWp-jN0bufhwmMLhVG5eQ-2knFgwzKyn9fvL2UF-FKdrzjVLRF8OJGEMPXucxETjZpcE55CHOSrGGcdi1hS67n_6G7MMcywkJxwvuGCt7cSTWc9m3diMX18kjpGFKKMN6WTIlcFkEuiyB_L0KBn_3d5C365-cLQI_AtXVwuEMlP26266P0FyhMwk0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2461953481</pqid></control><display><type>article</type><title>Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study</title><source>Wiley-Blackwell Open Access Collection</source><source>Wiley Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>Directory of Open Access Journals (Open Access)</source><creator>Hou, Yi‐Cheng ; Lai, Chien‐Wen ; Cheng, Ching‐Feng ; Lin, Yi‐Ying ; Hsieh, Tsung‐Han ; Hui Wu, Jing ; Tzeng, I‐Shiang ; Kuo, Chan‐Yen</creator><creatorcontrib>Hou, Yi‐Cheng ; Lai, Chien‐Wen ; Cheng, Ching‐Feng ; Lin, Yi‐Ying ; Hsieh, Tsung‐Han ; Hui Wu, Jing ; Tzeng, I‐Shiang ; Kuo, Chan‐Yen</creatorcontrib><description>Background
Type 2 diabetes mellitus (T2DM) is a condition involving several molecular mechanisms related to the intestinal microbiota for its development. Intestinal fatty acid‐binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. A prebiotic is a non‐digestible food ingredient that improves host health by selectively stimulating the growth and/or activities of bacteria in the colon. We aimed to clarify the currently described effects of prebiotics in the prevention and management of T2DM.
Methods
In this case‐control study, we chose 68 participants with T2DM and 52 healthy participants. Both groups were further divided based on consumption of prebiotics. Forty participants with T2DM consumed prebiotics, and 28 did not; 30 healthy volunteers consumed prebiotics, and 22 did not. We used the analysis of variance to compare the inflammation levels between the case and control groups. Multiple linear regression was performed for the significantly correlated groups to estimate the influence of prebiotics on inflammation level.
Results
Age was a significant factor for difference in I‐FABP levels (standardized coefficient: 0.06; P = .047). The analysis of eating habits showed that vegetarian diets produced lower I‐FABP levels than non‐vegetarian diets (standardized coefficient: −2.55; P = .022). Results showed that patients with T2DM who consumed prebiotics expressed lower I‐FABP levels, reflecting an improvement in inflammation level, than the healthy volunteers who did not consume prebiotics (standardized coefficient: −3.20; P = .019).
Conclusions
For patients with T2DM, prebiotics supplemented produced no significant impact on serum I‐FABP levels.
To evaluate effects of prebiotics in the prevention and management T2DM, totally 120 patients were recruited for the initial screening with I‐FABP. The participants in this study had no history of gastrointestinal disease and had not been treated with antibiotics or laxatives within 3 months before the experiment; all T2DM patients received dietary advice to control and treat diabetes. Blood or urine samples were collected at baseline and at 1, 3, and 6 months, followed by proper statistical analysis.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.23490</identifier><identifier>PMID: 32696562</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Blood pressure ; Body mass index ; Cholesterol ; Chronic illnesses ; Colon ; Cytokines ; Diabetes ; diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Fatty acid-binding protein ; Fatty acids ; Fermentation ; fructooligosaccharides ; Glucose ; Inflammation ; intestinal fatty acid‐binding protein ; Intestinal microflora ; Intestine ; Metabolism ; Microbiota ; Microorganisms ; Molecular modelling ; Patients ; Prebiotics ; Probiotics ; Proteins ; synbiotics ; Tumor necrosis factor-TNF ; Variance analysis ; Vegetarian diet</subject><ispartof>Journal of clinical laboratory analysis, 2020-11, Vol.34 (11), p.e23490-n/a</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC</rights><rights>2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4350-eba121daee400e6aaf2d8166c521aed1f16b20891f92da8d95a6122622879bd13</cites><orcidid>0000-0002-9047-8141</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676185/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676185/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1416,11560,27922,27923,45572,45573,46050,46474,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32696562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hou, Yi‐Cheng</creatorcontrib><creatorcontrib>Lai, Chien‐Wen</creatorcontrib><creatorcontrib>Cheng, Ching‐Feng</creatorcontrib><creatorcontrib>Lin, Yi‐Ying</creatorcontrib><creatorcontrib>Hsieh, Tsung‐Han</creatorcontrib><creatorcontrib>Hui Wu, Jing</creatorcontrib><creatorcontrib>Tzeng, I‐Shiang</creatorcontrib><creatorcontrib>Kuo, Chan‐Yen</creatorcontrib><title>Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background
Type 2 diabetes mellitus (T2DM) is a condition involving several molecular mechanisms related to the intestinal microbiota for its development. Intestinal fatty acid‐binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. A prebiotic is a non‐digestible food ingredient that improves host health by selectively stimulating the growth and/or activities of bacteria in the colon. We aimed to clarify the currently described effects of prebiotics in the prevention and management of T2DM.
Methods
In this case‐control study, we chose 68 participants with T2DM and 52 healthy participants. Both groups were further divided based on consumption of prebiotics. Forty participants with T2DM consumed prebiotics, and 28 did not; 30 healthy volunteers consumed prebiotics, and 22 did not. We used the analysis of variance to compare the inflammation levels between the case and control groups. Multiple linear regression was performed for the significantly correlated groups to estimate the influence of prebiotics on inflammation level.
Results
Age was a significant factor for difference in I‐FABP levels (standardized coefficient: 0.06; P = .047). The analysis of eating habits showed that vegetarian diets produced lower I‐FABP levels than non‐vegetarian diets (standardized coefficient: −2.55; P = .022). Results showed that patients with T2DM who consumed prebiotics expressed lower I‐FABP levels, reflecting an improvement in inflammation level, than the healthy volunteers who did not consume prebiotics (standardized coefficient: −3.20; P = .019).
Conclusions
For patients with T2DM, prebiotics supplemented produced no significant impact on serum I‐FABP levels.
To evaluate effects of prebiotics in the prevention and management T2DM, totally 120 patients were recruited for the initial screening with I‐FABP. The participants in this study had no history of gastrointestinal disease and had not been treated with antibiotics or laxatives within 3 months before the experiment; all T2DM patients received dietary advice to control and treat diabetes. Blood or urine samples were collected at baseline and at 1, 3, and 6 months, followed by proper statistical analysis.</description><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Cholesterol</subject><subject>Chronic illnesses</subject><subject>Colon</subject><subject>Cytokines</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Fatty acid-binding protein</subject><subject>Fatty acids</subject><subject>Fermentation</subject><subject>fructooligosaccharides</subject><subject>Glucose</subject><subject>Inflammation</subject><subject>intestinal fatty acid‐binding protein</subject><subject>Intestinal microflora</subject><subject>Intestine</subject><subject>Metabolism</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Molecular modelling</subject><subject>Patients</subject><subject>Prebiotics</subject><subject>Probiotics</subject><subject>Proteins</subject><subject>synbiotics</subject><subject>Tumor necrosis factor-TNF</subject><subject>Variance analysis</subject><subject>Vegetarian diet</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ksuKFDEUQIMoTju68QMk4EaEGpNUVSrlQmia8UWDG12HVHJrJk0qaZPUDL1z7cpv9EtM2eOgLgYCWeTccx-5CD2l5IwSwl7ttFNnrG56cg-tKOlFxQRr76MVEaKrBKH1CXqU0o4QInrKH6KTmvGet5yt0PfzcQSdEw4j3kcYbMhWYx18mqd9tsHjchLEecLWZ0jZeuXwqHI-YKWt-fntx2C9sf6ihIcM1mMHV-BSwfFeZQu-yK9tvsTGqgGK4jVeY60SlNCSJ8fgcMqzOTxGD0blEjy5uU_Rl7fnnzfvq-2ndx82622lm7olFQyKMmoUQEMIcKVGZgTlXLeMKjB0pHxgS6Njz4wSpm8Vp4xxxkTXD4bWp-jN0bufhwmMLhVG5eQ-2knFgwzKyn9fvL2UF-FKdrzjVLRF8OJGEMPXucxETjZpcE55CHOSrGGcdi1hS67n_6G7MMcywkJxwvuGCt7cSTWc9m3diMX18kjpGFKKMN6WTIlcFkEuiyB_L0KBn_3d5C365-cLQI_AtXVwuEMlP26266P0FyhMwk0</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Hou, Yi‐Cheng</creator><creator>Lai, Chien‐Wen</creator><creator>Cheng, Ching‐Feng</creator><creator>Lin, Yi‐Ying</creator><creator>Hsieh, Tsung‐Han</creator><creator>Hui Wu, Jing</creator><creator>Tzeng, I‐Shiang</creator><creator>Kuo, Chan‐Yen</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9047-8141</orcidid></search><sort><creationdate>202011</creationdate><title>Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study</title><author>Hou, Yi‐Cheng ; Lai, Chien‐Wen ; Cheng, Ching‐Feng ; Lin, Yi‐Ying ; Hsieh, Tsung‐Han ; Hui Wu, Jing ; Tzeng, I‐Shiang ; Kuo, Chan‐Yen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4350-eba121daee400e6aaf2d8166c521aed1f16b20891f92da8d95a6122622879bd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Cholesterol</topic><topic>Chronic illnesses</topic><topic>Colon</topic><topic>Cytokines</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Fatty acid-binding protein</topic><topic>Fatty acids</topic><topic>Fermentation</topic><topic>fructooligosaccharides</topic><topic>Glucose</topic><topic>Inflammation</topic><topic>intestinal fatty acid‐binding protein</topic><topic>Intestinal microflora</topic><topic>Intestine</topic><topic>Metabolism</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Molecular modelling</topic><topic>Patients</topic><topic>Prebiotics</topic><topic>Probiotics</topic><topic>Proteins</topic><topic>synbiotics</topic><topic>Tumor necrosis factor-TNF</topic><topic>Variance analysis</topic><topic>Vegetarian diet</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hou, Yi‐Cheng</creatorcontrib><creatorcontrib>Lai, Chien‐Wen</creatorcontrib><creatorcontrib>Cheng, Ching‐Feng</creatorcontrib><creatorcontrib>Lin, Yi‐Ying</creatorcontrib><creatorcontrib>Hsieh, Tsung‐Han</creatorcontrib><creatorcontrib>Hui Wu, Jing</creatorcontrib><creatorcontrib>Tzeng, I‐Shiang</creatorcontrib><creatorcontrib>Kuo, Chan‐Yen</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley Free Archive</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hou, Yi‐Cheng</au><au>Lai, Chien‐Wen</au><au>Cheng, Ching‐Feng</au><au>Lin, Yi‐Ying</au><au>Hsieh, Tsung‐Han</au><au>Hui Wu, Jing</au><au>Tzeng, I‐Shiang</au><au>Kuo, Chan‐Yen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2020-11</date><risdate>2020</risdate><volume>34</volume><issue>11</issue><spage>e23490</spage><epage>n/a</epage><pages>e23490-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Background
Type 2 diabetes mellitus (T2DM) is a condition involving several molecular mechanisms related to the intestinal microbiota for its development. Intestinal fatty acid‐binding protein (I‐FABP) is a sensitive marker to study enterocyte damage. A prebiotic is a non‐digestible food ingredient that improves host health by selectively stimulating the growth and/or activities of bacteria in the colon. We aimed to clarify the currently described effects of prebiotics in the prevention and management of T2DM.
Methods
In this case‐control study, we chose 68 participants with T2DM and 52 healthy participants. Both groups were further divided based on consumption of prebiotics. Forty participants with T2DM consumed prebiotics, and 28 did not; 30 healthy volunteers consumed prebiotics, and 22 did not. We used the analysis of variance to compare the inflammation levels between the case and control groups. Multiple linear regression was performed for the significantly correlated groups to estimate the influence of prebiotics on inflammation level.
Results
Age was a significant factor for difference in I‐FABP levels (standardized coefficient: 0.06; P = .047). The analysis of eating habits showed that vegetarian diets produced lower I‐FABP levels than non‐vegetarian diets (standardized coefficient: −2.55; P = .022). Results showed that patients with T2DM who consumed prebiotics expressed lower I‐FABP levels, reflecting an improvement in inflammation level, than the healthy volunteers who did not consume prebiotics (standardized coefficient: −3.20; P = .019).
Conclusions
For patients with T2DM, prebiotics supplemented produced no significant impact on serum I‐FABP levels.
To evaluate effects of prebiotics in the prevention and management T2DM, totally 120 patients were recruited for the initial screening with I‐FABP. The participants in this study had no history of gastrointestinal disease and had not been treated with antibiotics or laxatives within 3 months before the experiment; all T2DM patients received dietary advice to control and treat diabetes. Blood or urine samples were collected at baseline and at 1, 3, and 6 months, followed by proper statistical analysis.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>32696562</pmid><doi>10.1002/jcla.23490</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9047-8141</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8013 |
| ispartof | Journal of clinical laboratory analysis, 2020-11, Vol.34 (11), p.e23490-n/a |
| issn | 0887-8013 1098-2825 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7676185 |
| source | Wiley-Blackwell Open Access Collection; Wiley Journals; PubMed Central; EZB Electronic Journals Library; Directory of Open Access Journals (Open Access) |
| subjects | Blood pressure Body mass index Cholesterol Chronic illnesses Colon Cytokines Diabetes diabetes mellitus Diabetes mellitus (non-insulin dependent) Fatty acid-binding protein Fatty acids Fermentation fructooligosaccharides Glucose Inflammation intestinal fatty acid‐binding protein Intestinal microflora Intestine Metabolism Microbiota Microorganisms Molecular modelling Patients Prebiotics Probiotics Proteins synbiotics Tumor necrosis factor-TNF Variance analysis Vegetarian diet |
| title | Effects of prebiotic consumption on serum intestinal fatty acid‐binding protein levels in patients with diabetes: A case‐control study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T16%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20prebiotic%20consumption%20on%20serum%20intestinal%20fatty%20acid%E2%80%90binding%20protein%20levels%20in%20patients%20with%20diabetes:%20A%20case%E2%80%90control%20study&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Hou,%20Yi%E2%80%90Cheng&rft.date=2020-11&rft.volume=34&rft.issue=11&rft.spage=e23490&rft.epage=n/a&rft.pages=e23490-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.23490&rft_dat=%3Cproquest_pubme%3E2606941864%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2461953481&rft_id=info:pmid/32696562&rfr_iscdi=true |